Trialtrove(トライアルトローブ)は、下記に代表される4万以上の情報ソースから医薬品の臨床試験情報を収集し、臨床試験単位でレポート化するデータベースです。
Clinicaltrial.govの約3~4倍の臨床試験数を収録しているため圧倒的な情報量を誇ります。また、複数の情報源やプライマリーリサーチを組み合わせることで深みのある臨床試験情報を提供しています。全ての情報ソースにリンクを掲載することで、収録情報の透明性と信頼性を確保しています。
Trialtroveの代表的な情報源:
また、下記のようにあまり目にすることがない情報ソースもカバーすることで、データベースの精度を向上させています。
臨床試験に関して下記の詳細を把握できます。
Trialtroveを活用することで下記の質問に答えることができます。
オーストラリアでイベント開催!Bio Connections Australia/2018年11月13日&14日
オーストラリアが治験環境における国際競争力を高めています。毎年千件以上の新規臨床試験を開始しており、早期臨床試験の実施国として存在感を高めています。今回のイベントではオーストラリア産業界のトップリーダーや研究者に加え、世界中の製薬企業やバイオテック企業が一堂に会し、早期臨床試験の実施国としてオーストラリアのさらなる成長の可能性とその戦略的利用について議論します。詳細・お申込はこちら
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Despite the chaos felt in many other sectors during the COVID-19 pandemic, pharma IPOs experienced a banner year in 2020. Understand deal making trends and business strategies as In Vivo examines the emergence of special purpose acquisition companies (SPACs) in a data-packed infographic
Topic business-strategies
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
The rapid development of a vaccine to fight COVID-19 is an effort that will be discussed and admired for centuries to come. The effort to make and deliver the vaccines to those who are most at risk is a battle all of its own. Two manufacturers talk to In Vivo about managing roll out strategies when the whole world is watching.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Power your strongest strategy for the year ahead with insights from the Outlook 2021 report. A combination of Scrip’s Scrip 100, Medtech Insight’s Medtech 100, and In Vivo’s Outlook reports, Outlook 2021 is a comprehensive window into the key trends, challenges and opportunities impacting the biopharma, medtech, and generics sectors for the year to come.
Topic Outlook
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.
Topic brexit policy-and-regulation
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
FDA guidance updated in mid-April offered workarounds for trial sponsors attempting to conduct clinical studies in a time of travel limitations, staffing changes and heightened patient safety issues. For trials involving complex products and administration, such as cell and gene therapies, sponsors must determine whether modified protocols can still maintain trial integrity. If not, it may be time to press pause.
Topic Coronavirus fda
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Topic Coronavirus vaccines
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
In Vivo: 医療用医薬品・医療機器...
13 Apr 2021
In Vivo: 医療用医薬品・医療機器...
08 Apr 2021
In Vivo: 医療用医薬品・医療機器...
08 Apr 2021
In Vivo: 医療用医薬品・医療機器...
07 Apr 2021
In Vivo: 医療用医薬品・医療機器...
06 Apr 2021
In Vivo: 医療用医薬品・医療機器...
06 Apr 2021
In Vivo: 医療用医薬品・医療機器...
06 Apr 2021
In Vivo: 医療用医薬品・医療機器...
01 Apr 2021
In Vivo: 医療用医薬品・医療機器...
01 Apr 2021
In Vivo: 医療用医薬品・医療機器...
31 Mar 2021
In Vivo: 医療用医薬品・医療機器...
24 Mar 2021
In Vivo: 医療用医薬品・医療機器...
23 Mar 2021
In Vivo: 医療用医薬品・医療機器...
23 Mar 2021
In Vivo: 医療用医薬品・医療機器...
22 Mar 2021
In Vivo: 医療用医薬品・医療機器...
22 Mar 2021
USA
Laura specializes in
+34 year(s) experience
USA
Judy specializes in
+32 year(s) experience
USA
Karen specializes in
+31 year(s) experience
新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。
Eメール:inquiry.jp@informa.com
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。